Study aim: Evaluation of the effect of a herbal compound on patients with clinical and CT scan findings strongly suspected of COVID-19 Design: This study is a randomized controlled clinical trial in which patients will be simply selected from hospitalized patients with corona. Individuals with eligibility criteria will be randomly divided into two groups of intervention and control, and 30 patients will be enrolled in each group. The study is three-blinded and the patient, the nurse giving the medication, the data collector, and the data analyzer are not aware of the type of assignment. Settings and conduct: This study will be carried out at Imam Reza Hospital, one of the hospitals affiliated to Mashhad University of Medical Sciences. This hospital has been assigned for corona patients. This research will be carried out in March and April of 2020. Participants/Inclusion and exclusion criteria: Inclusion criteria: Hospitalized patients who are suspected to COVID- 19 based on clinical symptoms and computed tomography findings; Clinically classified as moderate and severe; No organ damage; age under 70 years; They are stable in cardiovascular status. Non-inclusion criteria: Pregnant and lactating women; End stage patients Intervention groups: This study consists of two groups. Intervention group will receive a herbal compound so-called Fluherb containing extracts of purslane, Plantain, hyssop, licorice and turmeric prepared in suspension dosage form. The control group received a placebo syrup. The intervention period is five days and the drug will be administered orally in three divided doses. Both groups receive all current treatments and will be matched according to clinical status. Main outcome variables: Changes in clinical conditions and severity of disease